Home / Market News / $EW
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

PROGRESS Trial Shows Edwards TAVR Superior to Clinical Surveillance for Moderate Aortic Stenosis

Nov 2, 2026, 7:07 PM UTC · Primary ticker $EW

Edwards Lifesciences announced positive results from its PROGRESS trial, showing TAVR is superior to clinical surveillance for moderate aortic stenosis, significantly reducing death or heart failure events. This positive clinical trial outcome is a strong catalyst for Edwards, potentially expanding the addressable market for its TAVR technology and reinforcing its leadership in the cardiovascular device space.

Edwards Lifesciences reported highly positive results from its PROGRESS trial, demonstrating that its TAVR technology is superior to clinical surveillance for patients with moderate aortic stenosis and at-risk features. This is a significant development because it expands the potential patient population for TAVR, moving beyond severe aortic stenosis to a broader, earlier-stage group. This directly benefits Edwards by increasing the addressable market for its flagship TAVR products, reinforcing its market leadership, and potentially accelerating revenue growth. Competitors like Medtronic and Boston Scientific, who also have TAVR offerings or are developing them, may face increased pressure as Edwards solidifies its position. In the short term, this news is a strong positive catalyst for EW stock. Long-term, it could drive a paradigm shift in the treatment of moderate aortic stenosis, leading to sustained growth for Edwards and potentially impacting the competitive landscape in cardiovascular devices.

$EW positive Successful clinical trial expands market
$MDT negative Competitor in TAVR market
$BSX negative Competitor in TAVR market
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.